Plasmakinetic enucleation of prostate versus 160-W laser photoselective vaporization for the treatment of benign prostatic hyperplasia

• Published in: Asian journal of andrology Vol. 19; no. 1; pp. 15 - 19
• Main Authors: Wang, Si-Jun, Mu, Xiao-Nan, Chen, Ji, Jin, Xun-Bo, Zhang, Shi-Bao, Zhang, Long-Yang
• Format: Journal Article
• Language: English
• Published: China Wolters Kluwer India Pvt. Ltd 01.01.2017; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Aged; Drug therapy; Electrosurgery - methods; electrosurgery; laser therapy; prostate; prostatic hyperplasia; transurethral resection of prostate; Humans; Kallikreins - blood; Laser Therapy - methods; Length of Stay; Lower Urinary Tract Symptoms - etiology; Lower Urinary Tract Symptoms - surgery; Male; Middle Aged; Observations; Original; Pharmacokinetics; Postoperative Complications - epidemiology; Prostate-Specific Antigen - blood; Prostatic hyperplasia; Prostatic Hyperplasia - blood; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - surgery; Quality of Life; Transurethral Resection of Prostate - methods; Treatment Outcome
• ISSN: 1008-682X; 1745-7262
• DOI: 10.4103/1008-682X.164199

To evaluate the safety and efficacy of plasmakinetic enucleation of the prostate （PKEP） for the treatment of symptomatic benign prostatic hyperplasia （BPH） compared with 160-W lithium triboride laser photoselective vaporization of the prostate （PVP）. From February 2011 to July 2012, a prospective nonrandomized study was performed. One-hundred one patients underwent PKEP, and 110 underwent PVP. No severe intraoperative complications were recorded, and none of the patients in either group required a blood transfusion. Shorter catheterization time （38.14 ± 23.64 h vs 72.54 ± 28.38 h, P 〈 0.001） and hospitalization （2.32 ± 1.25 days vs 4.07±1.23 days, P 〈 0.001） were recorded in the PVP group. At 12-month postoperatively, the PKEP group had a maintained and statistically improvement in International Prostate Symptom Score （IPSS） （4.07 ±2.07 vs 5.00 ±2.10; P〈 0.001）, quality of life （QoL） （1.08 ± 0.72 vs 1.35 ± 0.72; P= 0.007）, maximal urinary flow rate （Qmax） （24.75±5.87 ml s^-1 vs 22.03 ±5.04 ml s^-1; P 〈 0.001）, postvoid residual urine volume （PVR） （14,29 ± 6,97 ml vs 17.00±6.11 ml; P = 0,001）, and prostate-specific antigen （PSA） value （0.78 ±0.57 ng ml^-1 vs 1.27 ±1.07 ng ml^-1; P 〈 0.001）. Both PKEP and PVP relieve low urinary tract symptoms （LUTS） due to BPH with low complication rates. PKEP can completely remove prostatic adenoma while the total amount of tissue removed by PVP is less than that can be removed by PKER Based on our study of the follow-up, PKEP provides better postoperative outcomes than PVP.